A review of nevus-associated melanoma: What is the evidence?
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
15
01
2022
accepted:
15
06
2022
pubmed:
21
7
2022
medline:
15
10
2022
entrez:
20
7
2022
Statut:
ppublish
Résumé
Cutaneous melanoma may have an adjacent nevus remnant on histological examination in 30% of cases (nevus-associated melanoma, NAM), while it may appear de novo, without a precursor lesion, in the remaining 70% of cases. Nevus-associated melanoma and the concept of acquired melanocytic nevi serving as precursors of melanoma has long been considered as a controversial topic. This controversy is, in part, due to their overall low rate of transformation to melanoma and scarce data on the natural history of progression. Another matter of debate regarded the possibility that the reported differences in NAM vs. de novo melanoma were due to an underestimation of NAM in thicker lesions due to obliteration of the nevus component by the tumour. During the last few years, several evidence has accumulated in order to address these controversies. In this review, we present a comprehensive synthesis of the epidemiological, clinical, dermoscopic and genetic findings in NAM, including thin NAM, compared to de novo melanoma. Answering the questions on nevus-associated melanoma may provide further insight into the classification of these tumours and disentangle their biology and route of development from that of de novo melanoma.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1927-1936Informations de copyright
© 2022 European Academy of Dermatology and Venereology.
Références
Pampena R, Kyrgidis A, Lallas A, Moscarella E, Argenziano G, Longo C. A meta-analysis of nevus-associated melanoma: Prevalence and practical implications. J Am Acad Dermatol 2017; 77: 938-945 e934.
Yeh I, Bastian BC. Melanoma pathology: new approaches and classification. Br J Dermatol 2021; 185: 282-293.
Elder D, Barnhill RL, Bastian BC et al. Melanocytic tumour classification and the pathway concept of melanoma pathogenesis. In Elder DE, Massi D, Scolyer RA, Willemze R, eds. WHO Classification of Skin Tumours, Vol. 11, 4th edn. International Agency for Research on Cancer (IARC), France, 2018: 66-71.
Elder DE, Bastian BC, Cree IA, Massi D, Scolyer RA. The 2018 world health organization classification of cutaneous, mucosal, and uveal melanoma: detailed analysis of 9 distinct subtypes defined by their evolutionary pathway. Arch Pathol Lab Med 2020; 144: 500-522.
Pampena R, Lai M, Piana S, Lallas A, Pellacani G, Longo C. Nevus-associated melanoma: facts and controversies. G Ital Dermatol Venereol 2020; 155: 65-75.
Semsarian CR, Ma T, Nickel B et al. Do we need to rethink the diagnoses melanoma in situ and severely dysplastic naevus? Br J Dermatol 2022; 186: 1030-1032.
Gandini S, Sera F, Cattaruzza MS et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 2005; 41: 28-44.
Massi G, Bastian BC, LeBoit PE, Pirieto VG, Xu X. Melanocytic tumours arising in congenital naevi. In Elder DM, Scolyer RA, Willemze R, eds. WHO Classification of Skin Tumours, 4th edn. International Agency ofr Research on Cancer (IARC), France, 2018: 132-134.
Krengel S, Hauschild A, Schafer T. Melanoma risk in congenital melanocytic naevi: a systematic review. Br J Dermatol 2006; 155: 1-8.
Clark WH Jr, Elder DE, Guerry D, Epstein MN, Greene MH, Van Horn M. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 1984; 15: 1147-1165.
Tsao H, Bevona C, Goggins W, Quinn T. The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population-based estimate. Arch Dermatol 2003; 139: 282-288.
Bosch-Amate X, Podlipnik S, Riquelme-Mc Loughlin C et al. Clinicopathological, genetic and survival advantages of naevus-associated melanomas: a cohort study. Acta Derm Venereol 2021; 101: adv00425.
Dessinioti C, Geller AC, Stergiopoulou A et al. A multicentre study of naevus-associated melanoma vs. de novo melanoma, tumour thickness and body site differences. Br J Dermatol 2021; 185: 101-109.
Tas F, Erturk K. De novo and nevus-associated melanomas: different histopathologic characteristics but similar survival rates. Pathol Oncol Res. 2020; 26: 2483-2487.
Manrique-Silva E, Reyes-Garcia D, Folgado B et al. The proportion of nevus-associated invasive melanoma differs with Breslow thickness: A cross-sectional study of 1087 cutaneous melanomas. J Am Acad Dermatol 2019; 81: 852-854.
Scalvenzi M, Megna M, Costa C, Fabbrocini G, Villani A, Greco V. Cutaneous melanoma associated with naevi prevalence: A 15-year cross-sectional retrospective study. Australas J Dermatol 2020; 61: 39-42.
Alendar T, Kittler H. Morphologic characteristics of nevi associated with melanoma: a clinical, dermatoscopic and histopathologic analysis. Dermatol Pract Concept 2018; 8: 104-108.
Martin-Gorgojo A, Requena C, Garcia-Casado Z, Traves V, Kumar R, Nagore E. Dysplastic vs. Common naevus-associated vs. de novo melanomas: an observational retrospective study of 1,021 patients. Acta Derm Venereol 2018; 98: 556-562.
Pandeya N, Kvaskoff M, Olsen CM et al. Factors related to nevus-associated cutaneous melanoma: a case-case study. J Invest Dermatol 2018; 138: 1816-1824.
Pan Y, Adler NR, Wolfe R, McLean CA, Kelly JW. Nodular melanoma is less likely than superficial spreading melanoma to be histologically associated with a naevus. Med J Aust 2017; 207: 333-338.
Sheen YS, Liao YH, Lin MH et al. Clinicopathological features and prognosis of patients with de novo versus nevus-associated melanoma in Taiwan. PloS One 2017; 12: e0177126.
Cymerman RM, Shao Y, Wang K et al. De novo vs nevus-associated melanomas: differences in associations with prognostic indicators and survival. J Natl Cancer Inst 2016; 108: djw121.
Hacker E, Olsen CM, Kvaskoff M et al. Histologic and phenotypic factors and MC1R status associated with BRAF(V600E), BRAF(V600K), and NRAS mutations in a community-based sample of 414 cutaneous melanomas. J Invest Dermatol 2016; 136: 829-837.
Haenssle HA, Mograby N, Ngassa A et al. Association of patient risk factors and frequency of nevus-associated cutaneous melanomas. JAMA Dermatol 2016; 152: 291-298.
Lin WM, Luo S, Muzikansky A et al. Outcome of patients with de novo versus nevus-associated melanoma. J Am Acad Dermatol 2015; 72: 54-58.
Shitara D, Nascimento MM, Puig S et al. Nevus-associated melanomas: clinicopathologic features. Am J Clin Pathol. 2014; 142: 485-491.
Manganoni AM, Farisoglio C, Gavazzoni F, Facchetti F, Zanotti F, Calzavara-Pinton P. Nodular melanomas associated with nevi. J Am Acad Dermatol 2010; 63: e97.
Purdue MP, From L, Armstrong BK et al. Etiologic and other factors predicting nevus-associated cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev 2005; 14: 2015-2022.
Bevona C, Goggins W, Quinn T, Fullerton J, Tsao H. Cutaneous melanomas associated with nevi. Arch Dermatol 2003; 139: 1620-1624 discussion 1624.
Kaddu S, Smolle J, Zenahlik P, Hofmann-Wellenhof R, Kerl H. Melanoma with benign melanocytic naevus components: reappraisal of clinicopathological features and prognosis. Melanoma Res 2002; 12: 271-278.
Carli P, Massi D, Santucci M, Biggeri A, Giannotti B. Cutaneous melanoma histologically associated with a nevus and melanoma de novo have a different profile of risk: results from a case-control study. J Am Acad Dermatol 1999; 40: 549-557.
Massi D, Carli P, Franchi A, Santucci M. Naevus-associated melanomas: cause or chance? Melanoma Res 1999; 9: 85-91.
Skender-Kalnenas TM, English DR, Heenan PJ. Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma? J Am Acad Dermatol 1995; 33: 1000-1007.
Sagebiel RW. Melanocytic nevi in histologic association with primary cutaneous melanoma of superficial spreading and nodular types: effect of tumor thickness. J Invest Dermatol 1993; 100: 322S-325S.
Shitara D, Tell-Marti G, Badenas C et al. Mutational status of naevus-associated melanomas. Br J Dermatol 2015; 173: 671-680.
Broekaert SM, Roy R, Okamoto I et al. Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res 2010; 23: 763-770.
Bauer J, Buttner P, Murali R et al. BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res 2011; 24: 345-351.
Vu M, Adler NR, Wee E et al. Impact of naevus association on survival for nodular and superficial spreading melanomas. Br J Dermatol 2018; 179: 761-762.
Rashid S, Klebanov N, Lin WM, Tsao H. Unsupervised phenotype-based clustering of clinicopathologic features in cutaneous melanoma. JID Innov 2021; 1: 100047.
Green A. A theory of site distribution of melanomas: Queensland, Australia. Cancer Causes Control 1992; 3: 513-516.
Whiteman DC, Watt P, Purdie DM, Hughes MC, Hayward NK, Green AC. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst 2003; 95: 806-812.
Whiteman DC, Pavan WJ, Bastian BC. The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res 2011; 24: 879-897.
Shain AH, Bastian BC. From melanocytes to melanomas. Nat Rev Cancer 2016; 16: 345-358.
Whiteman DC, Parsons PG, Green AC. p53 expression and risk factors for cutaneous melanoma: a case-control study. Int J Cancer 1998; 77: 843-848.
Kvaskoff M, Pandeya N, Green AC et al. Site-specific determinants of cutaneous melanoma: a case-case comparison of patients with tumors arising on the head or trunk. Cancer Epidemiol Biomarkers Prev 2013; 22: 2222-2231.
Dessinioti C, Geller AC, Whiteman DC et al. Not all melanomas are created equal: A review and call for more research into nodular melanoma. Br J Dermatol 2021; 185: 700-710.
Bastian BC. The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol 2014; 9: 239-271.
Kim SY, Kim SN, Hahn HJ, Lee YW, Choe YB, Ahn KJ. Metaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanoma. J Am Acad Dermatol 2015; 72: 1036-1046 e1032.
Dessinioti C, Geller AC, Stergiopoulou A et al. Nevus count associations with thinner nodular or superficial spreading melanoma. Acta Derm Venereol 2019; 99: 614-615.
Yelamos O, Braun RP, Liopyris K et al. Dermoscopy and dermatopathology correlates of cutaneous neoplasms. J Am Acad Dermatol 2019; 80: 341-363.
Zalaudek I, Conforti C, Guarneri F et al. Clinical and dermoscopic characteristics of congenital and noncongenital nevus-associated melanomas. J Am Acad Dermatol 2020; 83: 1080-1087.
Reiter O, Kurtansky N, Nanda JK et al. The differences in clinical and dermoscopic features between in situ and invasive nevus-associated melanomas and de novo melanomas. J Eur Acad Dermatol Venereol 2021; 35: 1111-1118.
Pampena R, Manfreda V, Kyrgidis A et al. Digital dermoscopic changes during follow-up of de-novo and nevus-associated melanoma: a cohort study. Int J Dermatol 2020; 59: 813-821.
Alvarez Martinez D, Boehncke WH, Kaya G, Merat R. Recognition of early melanoma: a monocentric dermoscopy follow-up study comparing de novo melanoma with nevus-associated melanoma. Int J Dermatol 2018; 57: 692-702.
Shitara D, Nascimento M, Ishioka P et al. Dermoscopy of naevus-associated melanomas. Acta Derm Venereol 2015; 95: 671-675.
Stante M, Carli P, Massi D, de Giorgi V. Dermoscopic features of naevus-associated melanoma. Clin Exp Dermatol 2003; 28: 476-480.
Farnetani F, Scope A, Mazzoni L et al. A comparative dermoscopic and reflectance confocal microscopy study of naevi and melanoma with negative pigment network. J Eur Acad Dermatol Venereol 2019; 33: 2273-2282.
Visser M, Palstra RJ, Kayser M. Allele-specific transcriptional regulation of IRF4 in melanocytes is mediated by chromatin looping of the intronic rs12203592 enhancer to the IRF4 promoter. Hum Mol Genet 2015; 24: 2649-2661.
Gibbs DC, Ward SV, Orlow I et al. Functional melanoma-risk variant IRF4 rs12203592 associated with Breslow thickness: a pooled international study of primary melanomas. Br J Dermatol 2017; 177: e180-e182.
Gibbs DC, Orlow I, Bramson JI et al. Association of Interferon Regulatory Factor-4 Polymorphism rs12203592 With Divergent Melanoma Pathways. J Natl Cancer Inst 2016; 108: djw004.
Duffy DL, Iles MM, Glass D et al. IRF4 variants have age-specific effects on nevus count and predispose to melanoma. Am J Hum Genet 2010; 87: 6-16.
Thomas NE, Edmiston SN, Orlow I et al. Inherited genetic variants associated with melanoma BRAF/NRAS subtypes. J Invest Dermatol 2018; 138: 2398-2404.
Ward SV, Gibbs DC, Orlow I et al. Association of IRF4 SNP rs12203592 with melanoma-specific survival. Br J Dermatol 2020; 183: 163-165.
Guhan S, Klebanov N, Tsao H. Melanoma genomics: a state-of-the-art review of practical clinical applications. Br J Dermatol 2021; 185: 272-281.
Tsao H, Chin L, Garraway LA, Fisher DE. Melanoma: from mutations to medicine. Genes Dev 2012; 26: 1131-1155.
Roh MR, Eliades P, Gupta S, Tsao H. Genetics of melanocytic nevi. Pigment Cell Melanoma Res 2015; 28: 661-672.
Colebatch AJ, Ferguson P, Newell F et al. Molecular genomic profiling of melanocytic nevi. J Invest Dermatol 2019; 139: 1762-1768.
Poynter JN, Elder JT, Fullen DR et al. BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res 2006; 16: 267-273.
Kakavand H, Crainic O, Lum T et al. Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas. Pathology 2014; 46: 193-198.
Hacker E, Hayward NK. Germline MC1R variants and BRAF mutant melanoma. J Invest Dermatol 2008; 128: 2354-2356.
Tschandl P, Berghoff AS, Preusser M et al. NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi. PLoS One 2013; 8: e69639.
Dadzie OE, Yang S, Emley A, Keady M, Bhawan J, Mahalingam M. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis. Br J Dermatol 2009; 160: 368-375.
Bogdan I, Smolle J, Kerl H, Burg G, Boni R. Melanoma ex naevo: a study of the associated naevus. Melanoma Res 2003; 13: 213-217.
Demunter A, Stas M, Degreef H, De Wolf-Peeters C, van den Oord JJ. Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma. J Invest Dermatol 2001; 117: 1483-1489.
Shain AH, Yeh I, Kovalyshyn I et al. The genetic evolution of melanoma from precursor lesions. N Engl J Med 2015; 373: 1926-1936.
Shain AH, Bastian BC. The genetic evolution of melanoma. N Engl J Med 2016; 374: 995-996.
Shain AH, Joseph NM, Yu R et al. Genomic and transcriptomic analysis reveals incremental disruption of key signaling pathways during melanoma evolution. Cancer cell 2018; 34: 45-55 e44.
Zeng H, Judson-Torres RL, Shain AH. The evolution of melanoma - moving beyond binary models of genetic progression. J Invest Dermatol 2020; 140: 291-297.